Edition:
United States

Biotechnology & Medical Research

Page 2

BB Biotech FY Net Result Turns to Profit Of CHF 688 Million

Friday, 16 Feb 2018 01:00am EST

Feb 16 (Reuters) - BB BIOTECH AG ::FY NET GAIN OF CHF 688 MN COMPARED TO A NET LOSS OF CHF 802 MN IN PREVIOUS PERIOD.‍WILL PROPOSE AN ORDINARY DIVIDEND OF CHF 3.30 PER SHARE​.

United Therapeutics Settles Patent Litigation With Actavis Laboratories FL

Thursday, 15 Feb 2018 08:00pm EST

Feb 15 (Reuters) - United Therapeutics Corp ::UNITED THERAPEUTICS ANNOUNCES SETTLEMENT OF PATENT LITIGATION WITH ACTAVIS LABORATORIES FL, INC. RELATING TO ORENITRAM.‍ENTERED INTO A SETTLEMENT AGREEMENT WITH ACTAVIS LABORATORIES FL, INC RESOLVING ONGOING LITIGATION​.‍UNDER SETTLEMENT AGREEMENT, CO GRANTED TO ACTAVIS LICENSE TO MANUFACTURE AND COMMERCIALIZE GENERIC VERSION OF ORENITRAM.SAYS PARTIES WILL ALSO TERMINATE PENDING LITIGATION CONCERNING PATENTS RELATING TO ACTAVIS' ANDA..UNITED THERAPEUTICS - ‍LICENSE IN SETTLEMENT AGREEMENT DOES NOT PERMIT ACTAVIS TO MANUFACTURE GENERIC VERSION OF ANY OTHER UNITED THERAPEUTICS PRODUCT​.‍ AGREEMENT DOES NOT GRANT ACTAVIS ANY RIGHTS OTHER THAN THOSE REQUIRED TO LAUNCH ACTAVIS' GENERIC VERSION OF ORENITRAM​.

Dova Pharmaceuticals Reports Qtrly Loss Per Share $‍0.36​

Thursday, 15 Feb 2018 04:05pm EST

Feb 15 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS.DOVA PHARMACEUTICALS INC QTRLY LOSS PER SHARE $‍0.36​.

Cytokinetics Qtrly Net Loss Per Share $0.75

Thursday, 15 Feb 2018 04:00pm EST

Feb 15 (Reuters) - Cytokinetics Inc ::CYTOKINETICS, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS.‍ENROLLMENT IN GALACTIC-HF ON TRACK UNDER COLLABORATION WITH AMGEN; FINALIZING PLANS FOR SECOND PHASE 3 CLINICAL TRIAL IN 2018​.‍COMPANY ANTICIPATES CASH REVENUE WILL BE IN RANGE OF $17 TO $23 MILLION FOR 2018​.QTRLY NET LOSS PER SHARE $0.75.Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $25.6 MILLION -- THOMSON REUTERS I/B/E/S.

Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-AAT

Thursday, 15 Feb 2018 01:32pm EST

Feb 15 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR ARO-AAT.ARROWHEAD PHARMA- U.S. FDA GRANTED ORPHAN DRUG DESIGNATION TO ARO-AAT FOR TREATMENT OF A RARE GENETIC LIVER DISEASE.

Riot Blockchain Enters Definitive Agreement For Acquisition Of 3,800 S9 Bitcoin Miners

Thursday, 15 Feb 2018 08:30am EST

Feb 15 (Reuters) - Riot Blockchain Inc ::RIOT BLOCKCHAIN ENTERS DEFINITIVE AGREEMENT FOR THE ACQUISITION OF 3,800 S9 BITCOIN MINERS.RIOT BLOCKCHAIN - ‍ENTERED INTO A DEFINITIVE DEAL TO ACQUIRE ADDITIONAL CRYPTOCURRENCY MINING EQUIPMENT CONSISTING OF 3,800 ANTMINER S9 BITCOIN MINERS​.

Ironwood Pharmaceuticals Qtrly GAAP Net Income Per Share $0.08

Thursday, 15 Feb 2018 08:01am EST

Feb 15 (Reuters) - Ironwood Pharmaceuticals Inc ::Q4 REVENUE $94.2 MILLION.‍EXPECT TO GENERATE POSITIVE CASH FLOW IN 4Q 2018​.QTRLY TOTAL REVENUES $94.2 MILLION VERSUS $87.5 MILLION.QTRLY GAAP NET INCOME PER SHARE BASIC AND DILUTED $0.08 ‍​.Q4 REVENUE VIEW $88.9 MILLION -- THOMSON REUTERS I/B/E/S.EXPECTS TO USE LESS THAN $75 MILLION IN CASH FOR OPERATIONS IN 2018 ‍​.

Genocea Qtrly Loss Per Share $0.37

Thursday, 15 Feb 2018 08:00am EST

Feb 15 (Reuters) - Genocea Biosciences Inc ::GENOCEA REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.GENOCEA BIOSCIENCES - EXPECTS EXISTING CASH AND CASH EQUIVALENTS ARE SUFFICIENT TO SUPPORT ITS OPERATING EXPENSES & CAPEX REQUIREMENTS INTO H2 OF 2019.GENOCEA BIOSCIENCES INC QTRLY LOSS PER SHARE $0.37.

Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of Aro-Hbv For Treatment Of Hepatitis B

Thursday, 15 Feb 2018 07:30am EST

Feb 15 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF HEPATITIS B.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary